Few studies have specifically examined the efficacy of recombinant human bone morphogenetic protein-2 (rhBMP-2)/absorbable collagen sponge (ACS) in posterolateral lumbar spine fusion. The purpose of this study was to report the clinical outcomes in elderly patients treated with posterior C1-C2 fusion with iliac crest bone graft (ICBG) plus rhBMP-2/ACS vs ICBG alone. One hundred forty patients older than 60 years were enrolled in this prospective, randomized trial and underwent instrumented C1-C2 fusion. Patients were divided into 2 groups based on fusion material. The ICBG group comprised patients who received ICBG alone, and the rhBMP-2/ACS group comprised patients who received ICBG plus rhBMP-2/ACS. The groups were compared based on operative time, estimated blood loss, hospital length of stay, clinical results, perioperative complications, fusion rate, fusion time, and revision rate. There were no significant differences in operative time, estimated blood loss, length of stay, and intraoperative complications between the 2 groups. Improvements in visual analog scale scores and Japanese Orthopaedic Association scores over the 2-year followup period were similar between groups. The fusion rate was 82.4% (56 of 68) in the rhBMP-2/ACS group and 78.7% (52 of 66) in the ICBG group (P=.782). Mean fusion time was 11 days shorter in the rhBMP-2/ACS group (81.8±29.4 days) than in the ICBG group (92.9±23.7 days) (P=.034). There were more wound complications requiring treatment in the rhBMP-2/ACS group (n=6; 8.8%) than in the ICBG group (n=2; 3.0%), although this was not statistically significant (P=.118). The use of rhBMP-2/ACS for posterior C1-C2 fusion appears to result in a relatively shorter fusion time, but there may be an increased risk of posterior cervical wound complications.
R ecombinant human bone morphogenetic protein-2 (rhBMP-2) and an absorbable collagen sponge (ACS) (Infuse Bone Graft; Medtronic Sofamor Danek, Memphis, Tennessee) has been commercially available for 10 years. During that time, the majority of clinical use has been off-label in posteriorly based fusion procedures. Initial reports, comprising case series data, have examined the role of rhBMP-2/ACS as both an iliac crest bone graft (ICBG) supplement and an ICBG substitute. [1] [2] [3] In a study comparing ICBG plus rhBMP-2/ACS vs ICBG alone, large and more consistent fusion masses were seen with the addition of rhBMP-2/ACS. 2 A 50-patient prospective randomized pilot investigational device exemption study yielded similar results, reporting a 95% fusion rate with rhBMP-2/ACS and ceramic granules vs a 70% fusion rate with ICBG. 4 In a study of 91 patients undergoing both single-and multilevel lumbar fusions, evaluation by fine-cut computed tomography (CT) scan at 2 years postoperatively demonstrated equivalent fusion rates in the rhBMP-2/ ACS and ICBG groups. 5 Despite these encouraging reports, questions remain regarding the use of rhBMP-2/ACS for spine fusion.
Reported complications are rare. Multiple studies have reported no increase in complications when used in the posterolateral lumbar spine, whereas use for transforaminal interbody fusion has been associated with ectopic bone formation that may or may not be symptomatic. 1, 6, 7 Despite an initial US Food and Drug Administration (FDA)-sponsored randomized pilot trial of rhBMP-2 in the anterior cervical spine that showed no increase in complications, multiple subsequent studies with larger and less contained doses have reported an increase in soft tissue swelling complications that have occasionally been associated with airway compromise. [6] [7] [8] [9] [10] [11] Other authors have reported the safe and effective use of rhBMP-2 in the anterior cervical spine by using lower doses and containing the rhBMP-2 within the interbody device. 12, 13 In July 2008, the FDA issued a public health notification warning of life-threatening complications associated with the use of rhBMP-2 for cervical spine fusion. This followed multiple reports to the FDA and in the medical literature of postoperative swelling and airway compromise after anterior cervical fusion with rhBMP-2.
14 Another question is whether rhBMP-2/ ACS is safe and effective in an older patient population. Most of the literature regarding lumbar fusion in older patients has focused on the rate of complications. Only a small number of studies have reported on health-related quality of life outcomes in older patients, and none have specifically examined the role of fusion biologics in this population. Furthermore, it is unknown whether potential complications such as osteolysis, which has been reported with rhBMP-2 in interbody applications, might be problematic in older osteoporotic patients. 1, 8, 15 Despite the limited data, older patients would intuitively seem to be an ideal target population for an ICBG substitute because of their poorer-quality iliac crest bone and their higher risk for graft-associated complications. [15] [16] [17] [18] [19] [20] Based on these unanswered questions, the purpose of the current study was to report on clinical outcomes at 2-year follow-up in patients treated with posterior C1-C2 fusion with ICBG plus rhBMP-2/ ACS vs ICBG alone. The study population was limited to patients older than 60 years in an effort to generate an improved understanding of C1-C2 fusion in this understudied population. To the authors' knowledge, this is the first report of rh-BMP-2/ACS and C1-C2 fusion.
Materials and Methods
The study protocol was approved by the institutional review board of the authors' hospital.
One hundred forty patients were enrolled in a prospective, randomized trial of ICBG plus rhBMP-2/ACS vs ICBG alone for posterior cervical spine fusion performed between 2007 and 2009 in patients older than 60 years. Patients were included if they underwent instrumented atlantoaxial fusion for the treatment of atlantoaxial instability diseases. Patients with infection and tumor and patients who underwent a concomitant anterior fusion were excluded.
Of the 140 patients initially entered into the study protocol, 2-year follow-up data were available for 134 patients. Four patients were excluded in the perioperative period: 2 died and 2 changed physicians and refused postoperative follow-up. Two additional patients (1 in each group) died during the 2-year follow-up period.
Of the 134 patients with available follow-up data, 68 received ICBG plus rh-BMP-2/ACS and 66 received ICBG alone. There were no significant differences in age and sex distributions ( Table 1) .
surgical technique
Surgeries were performed by 1 of 4 fellowship-trained and experienced spine surgeons (L.Y., Z.C., B.R.H., D.J.H.).
A midline incision was made to expose the posterior elements of C1-C3; the medial and lateral margins of the lateral mass of the axis and the posterior surface of the posterior lamina of the atlas were dissected. All patients were stabilized with C1 lateral mass screws and C2 pedicle screws. Next, the rods were placed and secured in position. A cross-link between the C1 and C2 connectors can be used to increase rigidity in rotational and axial planes (Figure 1) . The posterior arch of C1 and the lamina of C2 were decorticated and bone graft used to provide bony fusion. In the ICBG group, autogenous iliac crest was harvested from a separate incision centered over the posterior superior iliac spine. In the rhBMP-2/ACS group, rhBMP-2/ACS (Infuse Bone Graft) was reconstituted according to the package labeling instructions and combined with local autograft in all cases. The same screw/ rod implant system was used in all cases. Deep drain was routinely used and discontinued on the second postoperative day. Antibiotics were given preoperatively and continued until the drain was removed.
All patients were managed by a uniform pre-and postoperative protocol, including patient-based outcome questionnaires, medical consultation, standard physical therapy regimen, and physiatry assessment. Preoperative demographic data, comorbidity profiles, and baseline health status measures were collected. The risk factors for pseudoarthrosis, such as osteoporosis and smoking, were also recorded. Perioperative clinical parameters, including operative time, estimated blood loss, hospital length of stay, and complications, were recorded. A dedicated research nurse followed all patients throughout their hospital stay, after discharge, and for 2 years postoperatively to identify any adverse events or additional outpatient medical care.
Patients were seen at the hospital at 4 weeks; 3, 6, and 9 months; and 1 and 2 years postoperatively. Japanese Orthopaedic Association (JOA) scores and pain visual analog scale (VAS) scores were recorded at each visit. For patients who required a revision procedure for nonunion, the last observation before the additional surgical procedure was performed using the last observation carried forward technique for all future observations.
In accordance with World Health Organization guidelines, osteoporosis was defined as a T-score less than -2.5 based on dual-energy x-ray absorptiometry. All patients with osteoporosis were taking bisphosphonates during the followup period. Smokers were defined as those who had continuously smoked for at least 1 year pre-and postoperatively. Patients with medical comorbidities were defined as those who were receiving treatment for 2 or more concurrent conditions, such as diabetes mellitus, hypertension, and thyroid disease. Revision surgeries were restricted to cases in which surgery was performed for pseudoarthrosis; surgeries due to infection and metal removal for irritation pain were excluded.
Fusion was evaluated by 3 orthopedic spine surgeons (B.R.H., T.J.L., D.J.H.), blinded to treatment group, based on CT scans performed using 1-mm slices with coronal and sagittal reconstructions. Patients who underwent a revision procedure were assigned a 2-year postoperative CT grade based on their findings at exploration. A mean fusion grade for each group was calculated.
A comparison between the 2 groups was made based on operative time, estimated blood loss, hospital length of stay, clinical results, perioperative complications, fusion rate, fusion time, and revision rate. A comparison was also made based on the presence or absence of risk factors for pseudoarthrosis.
Statistical analyses were performed using SPSS version 16.0 statistical software (SPSS, Inc, Chicago, Illinois). To detect significant differences between the rhBMP-2/ACS and ICBG groups, the chi-square test was used for dichotomous variables, the Mann-Whitney U test for noncontinuous ranked variables, and the unpaired t test for continuous variables. Two-sided P values were reported to compare differences between the groups. A P value less than .05 was considered statistically significant.
results
Mean operative time was 101±17 minutes in the rhBMP-2/ACS group and 96±14 minutes in the ICBG group. Mean estimated blood loss was 420±90 mL in the rhBMP-2/ACS group and 390±90 mL in the ICBG group. Mean hospital length of stay was 6.6±1.2 days in the rhBMP-2/ ACS group and 7.1±1.9 days in the ICBG group. Intraoperative complications included dural tears in 1 patient in the rh-BMP-2/ACS group and 1 patient in the ICBG group. There were no significant differences in operative time, estimated blood loss, hospital length of stay, and intraoperative complications between the 2 groups ( Table 2) . Mean VAS score in the rhBMP-2/ACS group was 7.8 preoperatively and 5.2 at 3 months, 3.7 at 6 months, 2.2 at 1 year, and 1.9 at 2 years postoperatively. Mean VAS score in the ICBG group was 7.6 preoperatively and 4.9 at 3 months, 4.0 at 6 months, 3.1 at 1 year, and 1.8 at 2 years postoperatively (Figure 2) . Mean JOA score in the rhBMP-2/ACS group was 3.0 preoperatively and 5.1 at 3 months, 10.7 at 6 months, 11.9 at 1 year, and 13.3 at 2 years postoperatively. Mean JOA score in the ICBG group was 3.2 preoperatively and 5.4 at 3 months, 9.7 at 6 months, 11.4 at 1 year, and 13.0 at 2 years postoperatively (Figure 3) . The improvement in VAS and JOA scores over the 2-year follow-up period was similar in both groups.
The Table 3) . There were more wound complications requiring treatment in the rhBMP-2/ ACS group (n=6; 8.8%) than in the ICBG group (n=2; 3.0%), although this was not statistically significant (P=.118). Four patients in the rhBMP-2/ACS group and 2 in the ICBG group with prolonged wound drainage from the posterior cervical wound were successfully treated with oral antibiotic therapy alone. Two deep surgical site infections presenting with wound drainage in the rhBMP-2/ACS group were successfully treated with irrigation and debridement followed by intravenous antibiotic therapy. Other perioperative complications in the rhBMP-2/ ACS group included cardiac (n=1), gastrointestinal (n=2), urinary tract infection (n=2), and deep venous thrombosis (n=1). Perioperative complications in the ICBG group included cardiac (n=3), gastrointestinal (n=4), urinary tract infection (n=3), and deep vein thrombosis (n=3). The difference in total number of complications between the groups was not statistically significant (P=.325) ( Table 4) .
discussion
Atlantoaxial instability may result from various pathologic conditions, including congenital malformations, trauma, neoplasm, and inflammatory diseases. In such conditions, atlantoaxial fixation may be required to correct the deformity, provide stability, and prevent neurological deficits. Although C1-C2 fusion surgery has become a common treatment for atlantoaxial instability diseases, many studies have found it difficult to achieve a highly successful fusion rate and good clinical outcomes in the elderly population with autograft, the current gold standard, due to the presence of multiple restricting factors. [21] [22] [23] Patients 60 years and older require a greater amount of autograft for successful fusion; however, elderly patients generally have poorer bone quality and potentially less bone available for harvest compared with their younger counterparts. Elderly patients may also have more overall health issues, with multiple medical comorbidities that contribute to the difficulty of achieving a successful fusion with autograft. For these reasons, numerous studies have reported poor surgical outcomes in elderly patients when autograft is used as a bone grafting material, 15, 17 thereby leading to the exploration of comparable alternatives. One possible alternative is to induce fusion with rhBMP-2. 3, 7, [24] [25] [26] In 2002, rhBMP-2/ACS was approved by the FDA as an ICBG replacement for use in conjunction with lordotic tapered cages in anterior lumbar interbody fusion. Since that time, rhBMP-2/ACS has been used extensively, but the primary application has been an off-label use in posterolateral spinal fusion or transforaminal lumbar interbody fusion. [1] [2] [3] Initial reports have been favorable. Boden et al 27 performed a prospective, randomized pilot trial of rhBMP-2 with 60% hydroxyapatite and 40% tricalcium phosphate granules vs iliac crest autograft. The authors reported increased fusion rates and better clinical outcomes in the rhBMP-2 group. Although the study population was small, no adverse outcomes related to rhBMP-2 were reported despite the relatively high concentration of rhBMP-2 used. Dimar et al 10 reported 2-year clinical outcomes and fusion success for single-level posterolateral lumbar fusion in 98 patients using rh-BMP-2 on a compression-resistant matrix (CRM) vs ICBG. There were significant clinical improvements in both groups at all time intervals, and these were not statistically different between groups. The rhBMP-2/CRM group had significantly higher fusion rates with less blood loss and shorter operative times. Again, there was no increase in wound complications or heterotopic bone formation despite the relatively high dose of rhBMP-2. Reports have consistently cited fusion rates that are equivalent or superior to autogenous iliac crest graft. 15, 18, 20 Although surgeons have constantly expanded their use of rhBMP-2/ACS to improve spinal fusion rates and avoid donor-site complications in spinal fusion surgery, to the current authors' knowledge, this study is the first prospective, randomized trial comparing ICBG plus rhBMP-2/ACS with ICBG alone for posterior C1-C2 fusion.
The study population, patients older than 60 years, was selected for several reasons. First, the limitation to older patients generates a more uniform set of preoperative diagnoses. Also, older patients seem to be ideal candidates for ICBG replacement because the quality of their iliac crest bone is often suboptimal, and their risk for complications from graft harvest and prolonged surgery is elevated.
There was no statistically significant difference in fusion rate between the groups in this study. The fusion rate was 82.4% (56 of 68) in the rhBMP-2/ACS group and 78.7% (52 of 66) in the ICBG group (P=.782). Nevertheless, mean fusion time was 11 days shorter in the rh-BMP-2/ACS group (81.8±29.4 days) than in the ICBG group (92.9±23.7 days). The similar fusion rate and shorter fusion time suggest that ICBG plus rhBMP-2/ACS may be used as an effective alternative to approve C1-C2 fusion in elderly patients. A possible reason is that rhBMP-2 induces mesenchymal stem cells to differentiate into osteoblasts or osteocytes through a cascade effect. Thus, rhBMP-2 could lead to bone and fusion formation by inducing the differentiation of osteocytes in elderly patients.
The results of the current study suggest that commercially available rhBMP-2/ ACS may have increased risk of severe posterior cervical wound complications There are several limitations to this study. First, a power analysis was not performed before the study. However, the authors reviewed related studies with a similar study design for sample size, and the current study's sample size was larger than that in most experiments. Second, CT scans were used to determine the presence of solid fusion because no definite or reliable methods have yet been established. In recent years, CT has been increasingly used in the assessment of fusion because it can clearly depict anatomical structures and connectivity between fusion masses. However, some studies have found that CT exhibits inadequate reliability, and its regular use in follow-up is further limited by its relatively high radiation exposure. 2, 5, 17 Third, the study cohort was relatively small and strictly limited to elderly patients; therefore, the findings of this study cannot be applied to a younger patient population. Finally, a longer follow-up would be needed to evaluate the long-term results and any long-term differences in clinical outcomes between the 2 groups.
conclusion
The use of rhBMP-2/ACS in posterior C1-C2 fusion appears to marginally improve fusion time, but there may be an increased risk of severe posterior cervical wound complication. Spine surgeons must continue to balance the inherent risks of surgical intervention with the expected benefits. New technologies, such as rhBMP, must be used cautiously as surgeons continue to learn more about their potential benefits and risks. Studies are needed to clarify these issues and to determine the optimal carrier, placement, and dosing in the posterior cervical spine.
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